|Keeping Multiplex Assays in Control
|Mon 4:00 PM - Track 2: Patents, FDA, Multiplex
|Stephen R. Master
University of Pennsylvania
|View Long Abstract
|Mass spectrometry provides an ideal platform for measuring multiplex panels of biomarkers in a clinical setting. Multiple biomarkers may be combined into a new, aggregate marker with potentially improved diagnostic performance. However, quality control measures utilized for uniplex clinical chemistry testing cannot be adequately scaled to encompass large multiplex assays. The solution to this problem depends on whether measured analytes are being used as individual markers or as an aggregate test that combines multiple markers (“patterns” vs. “panels”). We will discuss solutions for these two cases that can be applied to achieve defined quality control targets for multiplex MS assays.